GLOBAL ANTI-EPILEPTIC DRUGS MARKET ESTIMATED TO SOAR HIGHER DURING 2019 TO 2026

Posted by Nikita Manwar on October 1st, 2019

GMI Research has published a new study titled “Global Anti-Epileptic Drugs Market, By Spectrum Type (Narrow Spectrum and Broad Spectrum), By Drug (Phenytoin, Phenobarbital, Carbamazepine, Oxcarbazepine, Gabapentin, Pregabalin, Lacosamide, Vigabatrin, Valproic Acid, Lamotrigine, Topiramate, Zonisamide, Levetiracetam, Clonazepam, Rufinamide) and Geography – Opportunities & Forecast, 2019-2026”, which orates the future prospects set to strike the Anti-Epileptic Drugs Market during the forecast period.

The Global Anti-Epileptic Drugs Market was valued at USD 3,323.7 million in 2018, and is projected to reach USD 4,458.0 million by 2026, growing at a CAGR of 3.8% during 2019-2026. Alcoholism, smoking, Dietary habits and rising geriatric population are the major factor driving the antiepileptic drugs market. Additionally, wide availability of technically advanced Anti-Epileptic Drugs, improvement in diagnosis and treatment of epilepsy and rising demand for home based Anti-Epileptic Drugs treatment are likely to push the growth of global Anti-Epileptic Drugs market in the forecast years.

Antiepileptic drug can also be known as anti-seizure drug, developed for asymptomatic and Idiopathic treatment of epilepsy and seizures. Antiepileptic drugs can also be used for the treatment of neuropathic pain. Causes of epilepsy seizures are not defined or undetermined which has led many Antiepileptic drugs approved in the past years. Major factors which causes epilepsy include brain injury, stroke, and substance use disorders. Treatment of epilepsy, antiepileptic drugs or medicines (AEDs) are prescribed based on age of the patient, type of seizures to be treated, and which part of the brain is involved.

Based on Drug Valporic Acid (salt) is anticipated to lead the market during 2019-2026
Valporic Acid segment is expected to hold maximum share in the market during the forecast period due to effective drug structure and its usage in most type of seizures. However, the highest growth rate is predicted to be exhibited by Lacosamide during the forecast period owing to surging adoption of Anti-Epileptic Drugs market among healthcare professionals and patients due to its homogenous structure.

North America held the largest market share in global Anti-Epileptic Drugs market in 2018 owing to increasing social awareness, social acceptance, awareness among the population and government and private players inclination on Anti-Epileptic Drugs issues. Rest of the World is predicted to be the attractive regional market in global Anti-Epileptic Drugs market and is likely to show the maximum growth in the next few years.

Various notable players operating in global Anti-Epileptic Drugs market include Abbott Laboratories, Cephalon, Inc, Sunovion Pharmaceuticals, Valeant Pharmaceuticals International, Sanofi S.A, UCB Pharma Ltd, GlaxoSmithKline plc, Johnson & Johnson, Novartis, AG, Pfizer Inc among others.

The Global Anti-Epileptic Drugs Market has been segmented on the basis of spectrum type, drug type, and key geographies. Based on spectrum type, the market comprises of Narrow Spectrum and Broad Spectrum. The drug type includes Phenytoin, Phenobarbital, Carbamazepine, Oxcarbazepine, Gabapentin, Pregabalin, Lacosamide, Vigabatrin, Valproic Acid, Lamotrigine, Topiramate, Zonisamide, Levetiracetam, Clonazepam, Rufinamide

Key questions answered in this research report:
• At what pace is the Anti-Epileptic Drugs market growing worldwide? What will be the growth trend in future?
• What are the key drivers and restraints in the current market? What will be the impact of drivers and restraints in the coming years?
• What are the regional revenue and forecast breakdowns? Which are the major regional revenue pockets for growth in global Anti-Epileptic Drugs market?
• What are the various application areas and how they are poised to grow?

Market Segmentation
By Spectrum type
• arrow Spectrum
• Broad Spectrum

By Drug
• Phenytoin
• Phenobarbital
• Carbamazepine
• Oxcarbazepine
• Gabapentin
• Pregabalin
• Lacosamide
• Vigabatrin
• Valproic Acid
• Lamotrigine
• Topiramate
• Zonisamide
• Levetiracetam
• Clonazepam
• Rufinamide

By Geography
• North America
o By Spectrum type
o By Drug Type
o US
o Canada
o Mexico

• Europe
o By Spectrum type
o By Drug Type
o UK
o Germany
o Spain
o Rest of Europe

• Asia-Pacific
o By Spectrum type
o By Drug Type
o China
o Australia
o India
o Rest of APAC

• ROW
o By Spectrum type
o By Drug Type
o Brazil
o South Africa
o GCC countries
o Rest of world (remaining countries of the LAMEA region)

About GMI Research

GMI Research is a market research and consulting firm which provides research-based solutions to business executives and investment professionals so that they can make right business & investment decisions faster based on real facts. We help business leaders through independent fact-based insight, ensuring their business achieve success by beating the competition.

GMI Research leverages its industry expertise and experience to identify the industry trends, big opportunities and potential growth areas across industries. Our Syndicated reports provide actionable insights and covers industry trends, market drivers & restraints, macroeconomics factors, market estimates & forecasts, competitive landscape etc. which helps our clients to strengthen its market position by deploying specific strategies and actions that will lead to higher growth.

Media Contact
Company Name: GMI RESEARCH
Contact Person: Media Relations
Email: Send Email
Phone: +353 1 442 8820
Address:Level 1, The Chase Carmanhall Road, Sandyford Industrial Estate
City: Dublin
State: Dublin
Country: Ireland
Website: www.gmiresearch.com